ACAD
HealthcareACADIA Pharmaceuticals Inc.
$20.73-0.54 (-2.54%)
Prev Close
$21.27
Open
$21.41
High
$21.57
Low
$20.72
Volume
999.2K
Market Cap
$3.82B
P/E
9.01
Div Yield
—
Over the past 12 months, insider activity at ACADIA Pharmaceuticals Inc. (ACAD) has been exclusively selling, with 0 insider purchases totaling $0.00 and 17 insider sales totaling $2.67M. The most recent insider transaction was by Rhodes Jennifer J (officer: EVP, CHIEF LEGAL OFFICER, SEC), who sold $162.5K worth of shares on Feb 10, 2026. ACADIA Pharmaceuticals Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $3.82B.
Buys (12M)
0
$0.00
Sells (12M)
17
$2.67M
Net Activity
Net Seller
$2.67M
Active Insiders
6
last 12 mo
ACAD Price Chart
ACAD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026↗ | Rhodes Jennifer J | officer: EVP, CHIEF LEGAL OFFICER, SEC | Sell | 6,950 | $23.38 | $162.5K | 7,609 |
| Feb 6, 2026↗ | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Sell | 6,950 | $23.38 | $162.5K | 0 |
| Nov 17, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,084 | $23.69 | $96.8K | 0 |
| Nov 17, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,262 | $23.69 | $243.1K | 0 |
| Nov 10, 2025↗ | Daly James M | Director | Sell | 30,000 | $22.37 | $671.0K | 0 |
| Sep 12, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $23.65 | $82.7K | 0 |
| Sep 2, 2025↗ | GAROFALO ELIZABETH A. | Director | Sell | 1,600 | $25.98 | $41.6K | 0 |
| Aug 18, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 22,000 | $25.18 | $554.0K | 0 |
| Jun 4, 2025↗ | Brege Laura | Director | Sell | 14,446 | $21.78 | $314.6K | 0 |
| May 16, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,000 | $22.50 | $90.0K | 0 |
| May 16, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,000 | $25.00 | $50.0K | 0 |
| May 1, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,327 | $14.60 | $19.4K | 0 |
| May 1, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $14.60 | $51.1K | 0 |
| Apr 5, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,028 | $14.82 | $15.2K | 0 |
| Apr 5, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,708 | $14.82 | $40.1K | 0 |
| Mar 24, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,095 | $17.05 | $18.7K | 0 |
| Mar 24, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,171 | $17.05 | $54.1K | 0 |
| Mar 5, 2025↗ | GAROFALO ELIZABETH A. | Director | Sell | 4,919 | $18.23 | $89.7K | 0 |
| Feb 23, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 475 | $19.96 | $9.5K | 0 |
| Feb 23, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 773 | $19.96 | $15.4K | 0 |
| Nov 19, 2024↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,073 | $16.81 | $68.5K | 19,863 |
| Nov 19, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,259 | $16.81 | $172.5K | 53,302 |
| Nov 19, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 10,329 | $16.81 | $173.6K | 62,105 |
| Aug 20, 2024↗ | DAVIS STEPHEN | CEO | Sell | 31,747 | $15.28 | $485.1K | 186,555 |
| Aug 20, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 9,733 | $15.28 | $148.7K | 43,735 |
| Aug 20, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 9,534 | $15.28 | $145.7K | 52,177 |
| Jun 11, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 975 | $14.79 | $14.4K | 34,564 |
| May 3, 2024↗ | DAVIS STEPHEN | CEO | Sell | 11,427 | $16.94 | $193.6K | 155,231 |
| May 3, 2024↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,326 | $16.94 | $22.5K | 14,370 |
| May 3, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,503 | $16.94 | $59.3K | 32,053 |
| May 3, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 3,477 | $16.94 | $58.9K | 42,133 |
| Apr 9, 2024↗ | DAVIS STEPHEN | CEO | Sell | 26,574 | $17.87 | $474.9K | 161,983 |
| Apr 9, 2024↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,790 | $17.87 | $32.0K | 13,862 |
| Apr 9, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,716 | $17.87 | $48.5K | 28,742 |
| Apr 9, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 2,568 | $17.87 | $45.9K | 38,796 |
| Mar 27, 2024↗ | DAVIS STEPHEN | CEO | Sell | 17,714 | $17.90 | $317.1K | 118,842 |
| Mar 27, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 5,434 | $17.90 | $97.3K | 26,183 |
| Mar 27, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 5,140 | $17.90 | $92.0K | 36,340 |
| Feb 27, 2024↗ | DAVIS STEPHEN | CEO | Sell | 5,577 | $24.67 | $137.6K | 101,890 |
| Feb 27, 2024↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 474 | $24.67 | $11.7K | 11,391 |
| Feb 27, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 772 | $24.67 | $19.0K | 21,067 |
| Feb 27, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 624 | $24.67 | $15.4K | 31,432 |
| Jan 9, 2024↗ | DAVIS STEPHEN | CEO | Sell | 3,732 | $29.96 | $111.8K | 96,521 |
| Jan 9, 2024↗ | KIM AUSTIN D. | EVP,General Counsel, Secretary | Sell | 590 | $29.96 | $17.7K | 46,901 |
| Jan 9, 2024↗ | Teehan Brendan | EVP, COO, Head of Commercial | Sell | 731 | $29.96 | $21.9K | 30,949 |
| Dec 15, 2023↗ | Kihara James | Principal Accounting Officer | Sell | 2,000 | $28.30 | $56.6K | 11,025 |
| Nov 21, 2023↗ | Kihara James | Principal Accounting Officer | Sell | 1,985 | $22.64 | $44.9K | 13,025 |
| Nov 21, 2023↗ | Schneyer Mark C. | EVP, Chief Financial Officer | Sell | 5,108 | $22.64 | $115.6K | 20,486 |
| Nov 21, 2023↗ | Teehan Brendan | EVP, COO, Head of Commercial | Sell | 4,960 | $22.64 | $112.3K | 30,393 |
| Oct 6, 2023↗ | DAVIS STEPHEN | CEO | Sell | 51,563 | $21.96 | $1.13M | 89,131 |
Showing 1–50 of 106
1 / 3
ACAD Insider Buying Activity
The following table shows recent insider purchases of ACADIA Pharmaceuticals Inc. (ACAD) stock reported via SEC Form 4 filings.
No insider buying activity found for ACAD in the last 12 months.
ACAD Insider Selling Activity
The following table shows recent insider sales of ACADIA Pharmaceuticals Inc. (ACAD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026↗ | Rhodes Jennifer J | officer: EVP, CHIEF LEGAL OFFICER, SEC | Sell | 6,950 | $23.38 | $162.5K | 7,609 |
| Feb 6, 2026↗ | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Sell | 6,950 | $23.38 | $162.5K | 0 |
| Nov 17, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,084 | $23.69 | $96.8K | 0 |
| Nov 17, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,262 | $23.69 | $243.1K | 0 |
| Nov 10, 2025↗ | Daly James M | Director | Sell | 30,000 | $22.37 | $671.0K | 0 |
| Sep 12, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $23.65 | $82.7K | 0 |
| Sep 2, 2025↗ | GAROFALO ELIZABETH A. | Director | Sell | 1,600 | $25.98 | $41.6K | 0 |
| Aug 18, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 22,000 | $25.18 | $554.0K | 0 |
| Jun 4, 2025↗ | Brege Laura | Director | Sell | 14,446 | $21.78 | $314.6K | 0 |
| May 16, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,000 | $22.50 | $90.0K | 0 |
| May 16, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,000 | $25.00 | $50.0K | 0 |
| May 1, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,327 | $14.60 | $19.4K | 0 |
| May 1, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $14.60 | $51.1K | 0 |
| Apr 5, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,028 | $14.82 | $15.2K | 0 |
| Apr 5, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,708 | $14.82 | $40.1K | 0 |
| Mar 24, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,095 | $17.05 | $18.7K | 0 |
| Mar 24, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,171 | $17.05 | $54.1K | 0 |
| Mar 5, 2025↗ | GAROFALO ELIZABETH A. | Director | Sell | 4,919 | $18.23 | $89.7K | 0 |
| Feb 23, 2025↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 475 | $19.96 | $9.5K | 0 |
| Feb 23, 2025↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 773 | $19.96 | $15.4K | 0 |
| Nov 19, 2024↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,073 | $16.81 | $68.5K | 19,863 |
| Nov 19, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,259 | $16.81 | $172.5K | 53,302 |
| Nov 19, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 10,329 | $16.81 | $173.6K | 62,105 |
| Aug 20, 2024↗ | DAVIS STEPHEN | CEO | Sell | 31,747 | $15.28 | $485.1K | 186,555 |
| Aug 20, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 9,733 | $15.28 | $148.7K | 43,735 |
| Aug 20, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 9,534 | $15.28 | $145.7K | 52,177 |
| Jun 11, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 975 | $14.79 | $14.4K | 34,564 |
| May 3, 2024↗ | DAVIS STEPHEN | CEO | Sell | 11,427 | $16.94 | $193.6K | 155,231 |
| May 3, 2024↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,326 | $16.94 | $22.5K | 14,370 |
| May 3, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,503 | $16.94 | $59.3K | 32,053 |
| May 3, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 3,477 | $16.94 | $58.9K | 42,133 |
| Apr 9, 2024↗ | DAVIS STEPHEN | CEO | Sell | 26,574 | $17.87 | $474.9K | 161,983 |
| Apr 9, 2024↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,790 | $17.87 | $32.0K | 13,862 |
| Apr 9, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,716 | $17.87 | $48.5K | 28,742 |
| Apr 9, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 2,568 | $17.87 | $45.9K | 38,796 |
| Mar 27, 2024↗ | DAVIS STEPHEN | CEO | Sell | 17,714 | $17.90 | $317.1K | 118,842 |
| Mar 27, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 5,434 | $17.90 | $97.3K | 26,183 |
| Mar 27, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 5,140 | $17.90 | $92.0K | 36,340 |
| Feb 27, 2024↗ | DAVIS STEPHEN | CEO | Sell | 5,577 | $24.67 | $137.6K | 101,890 |
| Feb 27, 2024↗ | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 474 | $24.67 | $11.7K | 11,391 |
| Feb 27, 2024↗ | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 772 | $24.67 | $19.0K | 21,067 |
| Feb 27, 2024↗ | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 624 | $24.67 | $15.4K | 31,432 |
| Jan 9, 2024↗ | DAVIS STEPHEN | CEO | Sell | 3,732 | $29.96 | $111.8K | 96,521 |
| Jan 9, 2024↗ | KIM AUSTIN D. | EVP,General Counsel, Secretary | Sell | 590 | $29.96 | $17.7K | 46,901 |
| Jan 9, 2024↗ | Teehan Brendan | EVP, COO, Head of Commercial | Sell | 731 | $29.96 | $21.9K | 30,949 |
| Dec 15, 2023↗ | Kihara James | Principal Accounting Officer | Sell | 2,000 | $28.30 | $56.6K | 11,025 |
| Nov 21, 2023↗ | Kihara James | Principal Accounting Officer | Sell | 1,985 | $22.64 | $44.9K | 13,025 |
| Nov 21, 2023↗ | Schneyer Mark C. | EVP, Chief Financial Officer | Sell | 5,108 | $22.64 | $115.6K | 20,486 |
| Nov 21, 2023↗ | Teehan Brendan | EVP, COO, Head of Commercial | Sell | 4,960 | $22.64 | $112.3K | 30,393 |
| Oct 6, 2023↗ | DAVIS STEPHEN | CEO | Sell | 51,563 | $21.96 | $1.13M | 89,131 |
ACAD Insiders
Similar Stocks to ACAD
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B